A	O
Randomized	B:C0206035
Controlled	I:C0206035
Noninferiority	I:C0206035
Trial	I:C0206035
of	O
Single	O
Dose	O
of	O
Oral	O
Dexamethasone	O
Versus	O
5	O
Days	O
of	O
Oral	O
Prednisone	O
in	O
Acute	O
Adult	O
Asthma	O
Oral	O
dexamethasone	O
demonstrates	O
bioavailability	O
similar	O
to	O
that	O
of	O
oral	O
prednisone	O
but	O
has	O
a	O
longer	O
half	O
-	O
life	O
.	O

A	O
Randomized	O
Controlled	I:C0206035
Noninferiority	I:C0206035
Trial	I:C0206035
of	O
Single	O
Dose	O
of	O
Oral	O
Dexamethasone	O
Versus	O
5	O
Days	O
of	O
Oral	O
Prednisone	O
in	O
Acute	O
Adult	O
Asthma	B:C0004096
Oral	O
dexamethasone	O
demonstrates	O
bioavailability	O
similar	O
to	O
that	O
of	O
oral	O
prednisone	O
but	O
has	O
a	O
longer	O
half	O
-	O
life	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	B:C1696465
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	I:C1706712
for	O
persistent	O
or	O
worsening	O
asthma	O
within	O
14	O
days	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	B:C0542339
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	I:C1706712
for	O
persistent	O
or	O
worsening	O
asthma	O
within	O
14	O
days	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	B:C0581124
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	I:C1706712
for	O
persistent	O
or	O
worsening	O
asthma	O
within	O
14	O
days	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	B:C0581125
asthma	O
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	I:C1706712
for	O
persistent	O
or	O
worsening	O
asthma	O
within	O
14	O
days	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	B:C0349790
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	I:C1706712
for	O
persistent	O
or	O
worsening	O
asthma	O
within	O
14	O
days	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	B:C1706712
treatment	I:C1706712
for	O
persistent	O
or	O
worsening	O
asthma	O
within	O
14	O
days	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	I:C1706712
for	O
persistent	B:C3266628
or	O
worsening	O
asthma	O
within	O
14	O
days	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	O
treatment	I:C1706712
for	O
persistent	O
or	O
worsening	O
asthma	B:C0004096
within	O
14	O
days	O
.	O

Adult	O
emergency	O
department	O
patients	O
(	O
aged	O
18	O
to	O
55	O
years	O
)	O
were	O
randomized	B:C0034656
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
12	O
mg	O
of	O
oral	O
dexamethasone	O
with	O
4	O
days	O
of	O
placebo	O
or	O
a	O
5	O
-	O
day	O
course	O
of	O
oral	O
prednisone	O
60	O
mg	O
a	O
day	O
.	O

Adult	O
emergency	O
department	O
patients	O
(	O
aged	O
18	O
to	O
55	O
years	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
12	O
mg	O
of	O
oral	O
dexamethasone	O
with	O
4	O
days	O
of	O
placebo	B:C1696465
or	O
a	O
5	O
-	O
day	O
course	O
of	O
oral	O
prednisone	O
60	O
mg	O
a	O
day	O
.	O

Outcomes	O
including	O
relapse	O
were	O
assessed	O
by	O
a	O
follow	B:C0178941
-	I:C0178941
up	I:C0178941
telephone	I:C0178941
interview	I:C0178941
at	O
2	O
weeks	O
.	O

One	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	B:C0011777
and	O
203	O
prednisone	O
subjects	O
completed	O
the	O
study	O
regimen	O
and	O
telephone	O
follow	I:C0178941
-	I:C0178941
up	I:C0178941
.	O

One	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	O
and	O
203	O
prednisone	B:C0032952
subjects	O
completed	O
the	O
study	O
regimen	O
and	O
telephone	O
follow	I:C0178941
-	I:C0178941
up	I:C0178941
.	O

One	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	O
and	O
203	O
prednisone	O
subjects	O
completed	O
the	O
study	O
regimen	O
and	O
telephone	B:C0178941
follow	I:C0178941
-	I:C0178941
up	I:C0178941
.	O

The	O
dexamethasone	B:C0011777
group	O
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8	O
%	O
difference	O
between	O
groups	O
for	O
noninferiority	O
in	O
relapse	O
rates	O
within	O
14	O
days	O
(	O
12.1	O
%	O
versus	O
9.8	O
%	O
;	O
difference	O
2.3	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-	O
4.1	O
%	O
to	O
8.6	O
%	O
)	O
.	O

Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	B:C0019993
for	O
their	O
relapse	O
visit	O
(	O
dexamethasone	O
3.4	O
%	O
versus	O
prednisone	O
2.9	O
%	O
;	O
difference	O
0.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-	O
4.1	O
%	O
to	O
3.1	O
%	O
)	O
.	O

Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	O
for	O
their	O
relapse	O
visit	B:C1512346
(	O
dexamethasone	O
3.4	O
%	O
versus	O
prednisone	O
2.9	O
%	O
;	O
difference	O
0.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-	O
4.1	O
%	O
to	O
3.1	O
%	O
)	O
.	O

Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	O
for	O
their	O
relapse	O
visit	O
(	O
dexamethasone	B:C0011777
3.4	O
%	O
versus	O
prednisone	O
2.9	O
%	O
;	O
difference	O
0.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-	O
4.1	O
%	O
to	O
3.1	O
%	O
)	O
.	O

Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	O
for	O
their	O
relapse	O
visit	O
(	O
dexamethasone	O
3.4	O
%	O
versus	O
prednisone	B:C0032952
2.9	O
%	O
;	O
difference	O
0.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-	O
4.1	O
%	O
to	O
3.1	O
%	O
)	O
.	O

A	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	B:C0032952
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
.	O

A	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	O
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	B:C0581124
to	O
moderate	O
asthma	O
exacerbations	I:C0349790
.	O

A	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	O
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	B:C0581125
asthma	O
exacerbations	I:C0349790
.	O

A	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	O
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	O
to	O
moderate	O
asthma	B:C0349790
exacerbations	I:C0349790
.	O

Enhanced	O
compliance	B:C3714738
and	O
convenience	O
may	O
support	O
the	O
use	O
of	O
dexamethasone	O
regardless	O
.	O

Enhanced	O
compliance	O
and	O
convenience	O
may	O
support	O
the	O
use	O
of	O
dexamethasone	B:C0011777
regardless	O
.	O

